Cargando…

Orally administered cannabidiol does not produce false‐positive tests for Δ(9)‐tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000

Many jurisdictions use point‐of‐collection (POC) oral fluid testing devices to identify driving under the influence of cannabis, indexed by the presence of Δ(9)‐tetrahydrocannabinol (THC), an intoxicating cannabinoid, in oral fluid. Although the use of the non‐intoxicating cannabinoid, cannabidiol (...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCartney, Danielle, Kevin, Richard C., Suraev, Anastasia S., Irwin, Christopher, Grunstein, Ronald R., Hoyos, Camilla M., McGregor, Iain S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292716/ https://www.ncbi.nlm.nih.gov/pubmed/34412166 http://dx.doi.org/10.1002/dta.3153

Ejemplares similares

Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial
por: McCartney, Danielle, et al.
Publicado: (2022)

O006 Acute effects of combined cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) in insomnia disorder: A randomised, placebo-controlled trial using high-density EEG
por: Suraev, A, et al.
Publicado: (2022)

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence
por: Arnold, Jonathon C., et al.
Publicado: (2022)

Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
por: Suraev, Anastasia, et al.
Publicado: (2020)

Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research
por: McCartney, Danielle, et al.
Publicado: (2020)

Understanding the Molecular Aspects of Tetrahydrocannabinol and Cannabidiol as Antioxidants
por: Borges, Rosivaldo S., et al.
Publicado: (2013)

Toxicological Properties of Δ(9)-tetrahydrocannabinol and Cannabidiol
por: Černe, Katarina
Publicado: (2020)

Continuous-Flow Synthesis of Δ(9)-Tetrahydrocannabinol and Δ(8)-Tetrahydrocannabinol from Cannabidiol
por: Bassetti, Benedetta, et al.
Publicado: (2023)

Absence of Relevant Thermal Conversion of Cannabidiol to Tetrahydrocannabinol in E-Cigarette Vapor and Low-Tetrahydrocannabinol Cannabis Smoke
por: Hindelang, Pascal, et al.
Publicado: (2022)

Δ(9)-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure
por: Miller, Sally, et al.
Publicado: (2018)

Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms
por: Casarett, David J., et al.
Publicado: (2019)

Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions
por: Henson, Jeremy D., et al.
Publicado: (2022)

Cannabidiol and Tetrahydrocannabinol Use in Parkinson’s Disease: An Observational Pilot Study
por: Sousa, Amber, et al.
Publicado: (2023)

Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract
por: Wakshlag, Joseph J., et al.
Publicado: (2020)

Cannabidiol Does Not Convert to Δ(9)-Tetrahydrocannabinol in an In Vivo Animal Model
por: Wray, Louise, et al.
Publicado: (2017)

Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?
por: Lachenmeier, Dirk W., et al.
Publicado: (2023)

Cannabis, Cannabidiol Oils and Tetrahydrocannabinol—What Do Veterinarians Need to Know?
por: De Briyne, Nancy, et al.
Publicado: (2021)

Marijuana use in children: An update focusing on pediatric tetrahydrocannabinol and cannabidiol use
por: Stoner, Michael J., et al.
Publicado: (2022)

Comparative Metabolomic Profiling of the Metabolic Differences of Δ9-Tetrahydrocannabinol and Cannabidiol
por: Rao, Qianru, et al.
Publicado: (2022)

A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans
por: Nahler, Gerhard, et al.
Publicado: (2017)

Combinations of Cannabidiol and Δ(9)-Tetrahydrocannabinol in Reducing Chemotherapeutic Induced Neuropathic Pain
por: Sepulveda, Diana E., et al.
Publicado: (2022)

The “Next Day” Effects of Cannabis Use: A Systematic Review
por: McCartney, Danielle, et al.
Publicado: (2023)

P066 A randomised, double-blind, placebo-controlled, single-dose, crossover, pilot study investigating the effects of cannabinol (CBN) 30 mg and 300 mg on sleep architecture and next-day function in insomnia disorder
por: Lavender, I, et al.
Publicado: (2022)

Pen Wipings
Publicado: (1869)

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆(9)-tetrahydrocannabinol (THC) by vaporisation
por: Solowij, Nadia, et al.
Publicado: (2014)

Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the “weed,” a pharmacodynamic discussion
por: Boggs, Douglas Lee, et al.
Publicado: (2016)

Single and Synergistic Effects of Cannabidiol and Δ-9-Tetrahydrocannabinol on Zebrafish Models of Neuro-Hyperactivity
por: Samarut, Éric, et al.
Publicado: (2019)

Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases
por: Schräder, N.H.B., et al.
Publicado: (2018)

Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101
por: Stollenwerk, Todd M., et al.
Publicado: (2021)

Neuronal and Astrocytic Morphological Alterations Driven by Prolonged Exposure with Δ9-Tetrahydrocannabinol but Not Cannabidiol
por: Landucci, Elisa, et al.
Publicado: (2022)

α-Glucosidase inhibitory activity of cannabidiol, tetrahydrocannabinol and standardized cannabinoid extracts from Cannabissativa
por: Suttithumsatid, Wiwit, et al.
Publicado: (2022)

Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions
por: Brown, Joshua D.
Publicado: (2020)

Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder (‘CUPID’ study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial
por: Lavender, Isobel, et al.
Publicado: (2023)

Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function
por: Morgan, Celia J. A., et al.
Publicado: (2018)

Cannabidiol and the Remainder of the Plant Extract Modulate the Effects of Δ9-Tetrahydrocannabinol on Fear Memory Reconsolidation
por: Murkar, Anthony, et al.
Publicado: (2019)

Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition
por: Colizzi, Marco, et al.
Publicado: (2017)

Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature
por: Golombek, Patricia, et al.
Publicado: (2020)

Δ 9-Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels: An Assessment on Cannabis Duplicity
por: Chetia, Swapnali, et al.
Publicado: (2020)

The in vitro effect of delta-9-tetrahydrocannabinol and cannabidiol on whole blood viscosity, elasticity and membrane integrity
por: James, Tameika R., et al.
Publicado: (2022)

Individual and combined effects of cannabidiol and Δ(9)-tetrahydrocannabinol on striato-cortical connectivity in the human brain
por: Wall, Matthew B, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hij4m5c50kt9f1fc9jdbldt4k3